Repros Therapeutics news - financial analysts think Androxal / Enclomiphene is dead.

"This is best described as a drug candidate in search of an indication. The company originally tried to develop this for testosterone deficiency, but in the company’s own words: “After a Type "C" meeting held with the FDA on October 15, 2007, we believed that there was no clear clinical path to develop Androxal® for this indication in the U.S.” The company then tried to develop it for men of reproductive age with low testosterone levels who want to maintain their fertility while being treated for their low testosterone condition, but again in their own words: “Given that there is an acceptable treatment regimen for men with low testosterone, there is significant uncertainty as to whether or not an additional approach such as Androxal® would be approved by the FDA or accepted in the market.” Finally the company proposes to develop it for diabetes (presumably in men with low testosterone), but this is purely speculative and the company has not even filed an IND in this indication. Realistically the company would need $20 million and over a year to file an IND and enroll and complete a Phase II trial in this indication. "